LETICIA LÓPEZ-PEDRAZA

Prof. Dr. LETICIA LÓPEZ-PEDRAZA

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in International Journal of Nursing Knowledge
Verified
Journal Article
Closed access
PDF file
EREneida Rejane Rabelo-Silva
Eneida Rejane Rabelo-Silva
VMVanessa Monteiro Mantovani
Vanessa Monteiro Mantovani
LETICIA LÓPEZ-PEDRAZALETICIA LÓPEZ-PEDRAZA
LETICIA LÓPEZ-PEDRAZA
PCPatrícia Cristina Cardoso
Patrícia Cristina Cardoso
CLCamila Takao Lopes
Camila Takao Lopes
THTracy Heather Herdman
Tracy Heather Herdman
OBJECTIVES: To discuss priorities and possibilities for promoting international collaboration and new research evidence on NANDA International, Inc. (NANDA-I). METHODS: Theoretical reflection article based on the literature and the authors’ opinions on the subject matter, carried out by six research nurses. CONCLUSIONS: International research collaboration for NANDA-I allows the improvement of research production in an actual clinical setting, especially with multicenter and validation studies, conducted by researchers from different countries. This provides for improved understanding of patients’ experiences and may help to produce robust scientific evidence. IMPLICATIONS FOR NURSING KNOWLEDGE: The generation of new evidence may lead to an increase in NANDA-I visibility and in nurses’ understanding of its meaning for clinical practice and for the formulation of diagnostic hypotheses.

27 January 2022 in BMJ Quality & Safety
Verified
Journal Article
Open access
PDF file
EREneida Rejane Rabelo-Silva
Eneida Rejane Rabelo-Silva
SLSolange Antonia Lourenço
Solange Antonia Lourenço
RMRubia Natasha Maestri
Rubia Natasha Maestri
CLClaudia Candido da Luz
Claudia Candido da Luz
VPVanderlei Carlos Pupin
Vanderlei Carlos Pupin
ESEduardo Ferreira dos Santos
Eduardo Ferreira dos Santos
Background Little is known about peripherally inserted central catheter (PICC) use, appropriateness and device outcomes in Brazil. Methods We conducted an observational, prospective, cohort study spanning 16 Brazilian hospitals from October 2018 to August 2020. Patients ≥18 years receiving a PICC were included. PICC placement variables were abstracted from medical records. PICC-related major (deep vein thrombosis (DVT), central line-associated bloodstream infection (CLABSI) and catheter occlusion) and minor complications were collected. Appropriateness was evaluated using the Michigan Appropriateness Guide for Intravenous Catheters (MAGIC). Devices were considered inappropriate if they were in place for <5 days, were multi-lumen, and/or were placed in patients with a creatinine >2.0 mg/dL. PICCs considered appropriate met none of these criteria. Mixed-effects logistic regression models adjusting for patient-level and hospital-level characteristics assessed the association between appropriateness and major complications. Results Data from 12 725 PICCs were included. Mean patient age was 66.4±19 years and 51.0% were female. The most common indications for PICCs were intravenous antibiotics (81.1%) and difficult access (62.7%). Most PICCs (72.2%) were placed under ultrasound guidance. The prevalence of complications was low: CLABSI (0.9%); catheter-related DVT (1.0%) and reversible occlusion (2.5%). Of the 12 725 devices included, a total of 7935 (62.3%) PICCs were inappropriate according to MAGIC. With respect to individual metrics for appropriateness, 17.0% were placed for <5 days, 60.8% were multi-lumen and 11.3% were in patients with creatinine >2.0 mg/dL. After adjusting for patient and hospital-level characteristics, multi-lumen PICCs considered inappropriate were associated with greater odds of major complications (OR 2.54, 95% CI 1.61 to 4.02). Conclusions Use of PICCs in Brazilian hospitals appears to be safe and comparable with North America. However, opportunities to improve appropriateness remain. Future studies examining barriers and facilitators to improving device use in Brazil would be welcomed.

1 February 2024 in JAMA Cardiology
Verified
Journal Article
Closed access
PDF file
LRLuis E Rohde
Luis E Rohde
MRMarciane M Rover
Marciane M Rover
CFConrado R Hoffmann Filho
Conrado R Hoffmann Filho
EREneida Rejane Rabelo-Silva
Eneida Rejane Rabelo-Silva
OSOdilson M Silvestre
Odilson M Silvestre
MIMESSAGE-HF Investigators
MESSAGE-HF Investigators
Importance: Readmissions after an index heart failure (HF) hospitalization are a major contemporary health care problem.Objective: To evaluate the feasibility and efficacy of an intensive telemonitoring strategy in the vulnerable period after an HF hospitalization.Design, Setting, and Participants: This randomized clinical trial was conducted in 30 HF clinics in Brazil. Patients with left ventricular ejection fraction less than 40% and access to mobile phones were enrolled up to 30 days after an HF admission. Data were collected from July 2019 to July 2022.Intervention: Participants were randomly assigned to a telemonitoring strategy or standard care. The telemonitoring group received 4 daily short message service text messages to optimize self-care, active engagement, and early intervention. Red flags based on feedback messages triggered automatic diuretic adjustment and/or a telephone call from the health care team.Main Outcomes and Measures: The primary end point was change in N-terminal pro–brain natriuretic peptide (NT-proBNP) from baseline to 180 days. A hierarchical win-ratio analysis incorporating blindly adjudicated clinical events (cardiovascular deaths and HF hospitalization) and variation in NT-proBNP was also performed.Results: Of 699 included patients, 460 (65.8%) were male, and the mean (SD) age was 61.2 (14.5) years. A total of 352 patients were randomly assigned to the telemonitoring strategy and 347 to standard care. Satisfaction with the telemonitoring strategy was excellent (net promoting score at 180 days, 78.5). HF self-care increased significantly in the telemonitoring group compared with the standard care group (score difference at 30 days, −2.21; 95% CI, −3.67 to −0.74; P = .001; score difference at 180 days, −2.08; 95% CI, −3.59 to −0.57; P = .004). Variation of NT-proBNP was similar in the telemonitoring group compared with the standard care group (telemonitoring: baseline, 2593 pg/mL; 95% CI, 2314-2923; 180 days, 1313 pg/mL; 95% CI, 1117-1543; standard care: baseline, 2396 pg/mL; 95% CI, 2122-2721; 180 days, 1319 pg/mL; 95% CI, 1114-1564; ratio of change, 0.92; 95% CI, 0.77-1.11; P = .39). Hierarchical analysis of the composite outcome demonstrated a similar number of wins in both groups (telemonitoring, 49 883 of 122 144 comparisons [40.8%]; standard care, 48 034 of 122 144 comparisons [39.3%]; win ratio, 1.04; 95% CI, 0.86-1.26).Conclusions and Relevance: An intensive telemonitoring strategy applied in the vulnerable period after an HF admission was feasible, well-accepted, and increased scores of HF self-care but did not translate to reductions in NT-proBNP levels nor improvement in a composite hierarchical clinical outcome.Trial Registration: ClinicalTrials.gov Identifier: NCT04062461

17 February 2022 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
PDF file
LLLeticia Leon
Leticia Leon
IPInes Perez-Sancristobal
Ines Perez-Sancristobal
AMAlfredo Madrid
Alfredo Madrid
LETICIA LÓPEZ-PEDRAZALETICIA LÓPEZ-PEDRAZA
LETICIA LÓPEZ-PEDRAZA
JCJose Ignacio Colomer
Jose Ignacio Colomer
LALydia Abasolo
Lydia Abasolo
We aimed to describe persistent symptoms and sequelae in patients with rheumatic and musculoskeletal diseases (RMD) after admission owing to coronavirus disease 2019 (COVID-19), assessing the role of autoimmune rheumatic diseases (ARDs) compared with non-autoimmune rheumatic and musculoskeletal diseases (NARDs) on persistent symptoms and sequelae. We performed an observational study including RMD patients who attended a rheumatology clinic in Madrid and required admission owing to COVID-19 (between March and May 2020) and survived. The study began at discharge and ran until October 2020. Main outcomes were persistence of symptoms and sequelae related to COVID-19. The independent variable was the RMD group (ARD and NARD). Covariates included sociodemographics, clinical and treatment data. We ran a multivariate logistic regression model to assess the risk of the main outcomes by RMD group. We included 105 patients, of whom 51.5% had ARD and 68.57% reported at least one persistent symptom. The most frequent symptoms were dyspnoea, fatigue and chest pain. Sequelae were recorded in 31 patients. These included lung damage in 10.4% of patients, lymphopenia in 10%, a central retinal vein occlusion and an optic neuritis. Two patients died. Eleven patients required re-admission owing to COVID-19 problems (16.7% ARD vs 3.9% NARD; P = 0.053). No statistically significant differences were found between RMD groups in the final models. Many RMD patients have persistent symptoms, as in other populations. Lung damage is the most frequent sequela. Compared with NARD, ARD does not seem to differ in terms of persistent symptoms or consequences, although ARD might have more re-admissions owing to COVID-19.

1 January 2019 in Revista Gaucha de Enfermagem
Verified
Journal Article
Open access
PDF file
CECarolina Mirapalheta Ernandes
Carolina Mirapalheta Ernandes
DBDaniela de Souza Bernardes
Daniela de Souza Bernardes
VMVanessa Monteiro Mantovani
Vanessa Monteiro Mantovani
LETICIA LÓPEZ-PEDRAZALETICIA LÓPEZ-PEDRAZA
LETICIA LÓPEZ-PEDRAZA
EREneida Rejane Rabelo-Silva
Eneida Rejane Rabelo-Silva
Resumo OBJETIVOS Analisar a acurácia diagnóstica de enfermagem em pacientes com predição de risco de piora clínica durante internação por insuficiência cardíaca agudamente descompensada. MÉTODO Estudo de coorte com coleta de dados em prontuário de acordo com o Acute Decompensated Heart Failure National Registry risk model. Após a definição dos pacientes em risco, aplicou-se a Escala de Acurácia de Diagnósticos de Enfermagem versão 2. A escala classifica a acurácia em nula, baixa, moderada ou alta. RESULTADOS Dos 43 pacientes com risco de piora, 22(51%) não pioraram e 21(49%) pioraram; em ambos, a acurácia diagnóstica apresentou-se na categoria Moderada/Alta em 22(89%) e 16(88%), respectivamente. Apenas Débito cardíaco diminuído e Volume de líquidos excessivo foram pontuados com 100% na categoria Alta. CONCLUSÕES Pacientes agudamente descompensados e com risco de piora clínica durante a internação foram identificados com acurácia diagnóstica Moderada ou Alta pelos enfermeiros.

18 September 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
LRLuis E. Rohde
Luis E. Rohde
CFConrado R. Hoffmann Filho
Conrado R. Hoffmann Filho
MRMarciane M. Rover
Marciane M. Rover
EREneida Rejane Rabelo-Silva
Eneida Rejane Rabelo-Silva
LETICIA LÓPEZ-PEDRAZALETICIA LÓPEZ-PEDRAZA
LETICIA LÓPEZ-PEDRAZA
FRFelix Ramirez
Felix Ramirez
Aims: To evaluate a telemonitoring strategy based on automated text messaging and telephone support after heart failure (HF) hospitalization. Methods and results: The MESSAGE-HF study is a prospective multicentre, randomized, nationwide trial enrolling patients from 30 clinics in all regions of Brazil. HF patients with reduced left ventricular ejection fraction (<40%) and access to mobile phones are eligible after an acute decompensated HF hospitalization. Patients meeting eligibility criteria undergo an initial feasibility text messaging assessment and are randomized to usual care or telemonitoring intervention. All patients receive a HF booklet with basic information and recommendations about self-care. Patients in the intervention group receive four daily short text messages (educational and feedback) during the first 30 days of the protocol to optimize self-care; the feedback text messages from patients could trigger diuretic adjustments or a telephone call from the healthcare team. After 30 days, the frequency of text messages can be adjusted. Patients are followed up after 30, 90, and 180 days, with final status ascertained at 365 days by telephone. Our primary endpoint is the change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after 180 days. Secondary endpoints include changes in NT-proBNP after 30 days; health-related quality of life, HF self-care, and knowledge scales after 30 and 180 days; and a composite outcome of HF hospitalization and cardiovascular death, adjudicated by a blinded and independent committee. Conclusions: The MESSAGE-HF trial is evaluating an educational and self-care promotion strategy involving a simple, intensive, and tailored telemonitoring system. If proven effective, it could be applied to a broader population worldwide.